The precision medicine research spinout from Cold Spring Habor Laboratory has secured seed capital in a round led by Dynamk Capital. Envisagenics, a US-based precision medicine research spinout from Cold Spring Harbor Laboratory, secured $2.25m in a seed round today led by VC fund Dynamk Capital. Dynamk committed $500,000 to the round, investing alongside a group of unnamed private investors. Founded in 2014, Envisagenics has developed a drug discovery platform that aims to provide researchers with… This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
A US medical research start-up that uses artificial intelligence (AI) to detect diseases has secured 2.25 of funding. Envisagenics is a spin-off from the non-profit private research institute the Cold Spring Harbor Laboratory in New York state, which specialises in molecular biology, neuroscience and genetics. Envisagenics was formed in 2014 and has developed a system that uses machine learning to detect and analyse genetic deformities called splicing errors that can indicate diseases. The investment round was led by venture capital firm Dynamk Capital, and comes after an undisclosed sum received in April from the Thiel Foundation.